Just reported
From Pfizer's results release of 3 noiembrie 2026; its quarterly report has since been filed.
Actual
16,58B USD
-0,4 % y/y
+10 % q/q
Guided
—
No guide given
Actual
0,56 USD
-9,7 % y/y
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Pfizer is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Ponderile din venituri sunt estimări pentru year ended December 31, 2025, high confidence, nu cifre dintr-un raport depus.
Eliquis
A prescription medicine that helps prevent blood clots and strokes in certain patients. Pfizer shares its development and commercial profits with Bristol Myers Squibb.
Pfizer vaccine portfolio
Vaccines include the Prevnar family for pneumococcal disease, Comirnaty to help prevent coronavirus disease, and Abrysvo for respiratory syncytial virus.
Paxlovid
A prescription medicine used to treat coronavirus disease.
Oncology medicines
Cancer medicines include Ibrance for breast cancer, Padcev for bladder cancer, and Xtandi for prostate cancer.
Nurtec ODT and Vydura
Migraine medicines. ODT means orally disintegrating tablet.
Vyndaqel family
Medicines for transthyretin amyloidosis, a disease in which an abnormal protein builds up in the body and can damage the heart or nerves.
Situațiile financiare complete →
Pfizer discovers, tests, manufactures, markets and sells medicines and vaccines around the world. Its products address conditions including cancer, heart and blood-vessel diseases, migraine, infections, immune disorders and rare diseases. It also makes medicines and drug ingredients for other companies and is winding down a research-services business for biotechnology companies.
Construit din raportările proprii ale Pfizer Inc. la Comisia pentru Valori Mobiliare și Burse a SUA (SEC). Cifrele sunt cele raportate, iar istoricul pe acțiune este recalculat la baza de acțiuni de azi. Aceasta descrie o afacere — nu este consultanță de investiții și nu este o recomandare de cumpărare sau vânzare.
29,45 USD+0,3 %închidere 11 nov.
Cifre până la 27 septembrie 2026, din 10-Q depus pe 3 noiembrie 2026
Pfizer develops, makes and sells prescription medicines and vaccines, and earns additional fees and royalties from manufacturing and commercial partnerships.
Grade C
Banda de sub preț arată nota la fiecare dată, calculată doar din documentele publice până atunci.
Se afișează 2 din 41 trimestre din istoricul notelor companiei Pfizer Inc.. Celelalte 39 merg înapoi până în noiembrie 2016.